相关实验视频

Updated: Jul 26, 2025

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

开发和评估Zr-trastuzumab用于临床应用

Fatemeh Mohammadpour-Ghazi¹, Hassan Yousefnia¹, GhasemAli Divband²

¹Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.

Asia Oceania journal of nuclear medicine & biology

|June 16, 2023

概括

这项研究开发了[89Zr]Zr-Trastuzumab用于HER2+瘤的PET成像. 放射性免疫结合物显示出高瘤吸收率和诊断HER2+转移的潜力.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射化学放射化学是指辐射化学.

背景情况:

人体表皮生长因子受体2 (HER2) 是乳腺癌治疗的目标.
特拉斯图祖马布是一种向HER2的单克隆抗体.
[89Zr]Zr-Trastuzumab将Trastuzumab的向与-89.9的PET成像能力相结合.

研究的目的:

准备和评估[89Zr]Zr-Trastuzumab作为用于HER2阳性瘤的PET成像剂.
评估[89Zr]Zr-Trastuzumab的临床前疗效和生物分布.
在患有HER2阳性转移性乳腺癌的患者中,将[89Zr]Zr-Trastuzumab PET/CT与[18F]FDG PET/CT进行比较.

主要方法:

使用旋转机生产89Zr.
将DFO与Trastuzumab结合,然后用89Zr进行标记.
在体外测试 (细胞结合,内化,放射性免疫活性) 使用HER2+和HER2-细胞系.
在瘤携带小鼠的体内生物分布和成像研究.
在患有HER2阳性转移性乳腺癌的患者中进行PET/CT成像.

主要成果:

实现了89Zr和[89Zr]Zr-DFO-Trastuzumab的高放射性核和放射性化学纯度.
放射性免疫结合物表现出稳定性以及对HER2+细胞的特定结合和内部化.
在小鼠中的生物分布研究显示,瘤部位的显著吸收.
[89Zr]Zr-Trastuzumab PET/CT在患者中成功发现了转移性病变,补充了 [18F]FDG PET/CT的发现.

结论:

[89Zr]Zr-Trastuzumab是一种有前途的放射性药物,用于对HER2阳性瘤的免疫PET成像.
这种药物可以划分HER2+转移,有助于诊断和治疗选择.
这项研究强调了[89Zr]Zr-Trastuzumab在个性化瘤学中的潜力.

关键词:

89ZrZr 89ZrZr 89ZrZr 89Zr 乳腺癌乳腺癌乳腺癌在HER2阳性瘤中.这就是Trastuzumab.

更多相关视频

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...